Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
Jacques De Grève*, Teresa Moran, Marie Pascale Graas, Daniella Galdermans, Peter Vuylsteke, Jean Luc Canon, Denis Schallier, Lore Decoster, Erik Teugels, Dan Massey, Vikram K. Chand, Johan Vansteenkiste
Navegar pels temes de recerca de 'Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma'. Junts formen un fingerprint únic.